ARTICLE | Clinical News
Sacituzumab govitecan: Additional Phase I/II data
January 26, 2015 8:00 AM UTC
Data from 23 evaluable heavily pretreated patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC) who had ³1 post-treatment CT assessment in an open-label, U.S. Phase I/II...